Tamoxifen's protection against breast cancer recurrence is not reduced by concurrent use of the SSRI citalopram

Tamoxifen remains an important adjuvant therapy to reduce the rate of breast cancer recurrence among patients with oestrogen-receptor-positive tumours. Cytochrome P-450 2D6 metabolises tamoxifen to metabolites that more readily bind the oestrogen receptor. This enzyme also metabolises selective sero...

Descripción completa

Detalles Bibliográficos
Autores principales: Lash, T L, Pedersen, L, Cronin-Fenton, D, Ahern, T P, Rosenberg, C L, Lunetta, K L, Silliman, R A, Hamilton-Dutoit, S, Garne, J P, Ewertz, M, Sørensen, H T
Formato: Texto
Lenguaje:English
Publicado: Nature Publishing Group 2008
Materias:
Clinical Study
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2527838/
https://www.ncbi.nlm.nih.gov/pubmed/18665165
http://dx.doi.org/10.1038/sj.bjc.6604533

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2527838/
https://www.ncbi.nlm.nih.gov/pubmed/18665165
http://dx.doi.org/10.1038/sj.bjc.6604533

Ejemplares similares